Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone

Journal of Clinical Psychiatry

Volumn 73, Issue 3, 2012, Pages 367-371

  Fijal, Bonnie A ^a   Stauffer, Virginia L ^a   Kinon, Bruce J ^a   Conley, Robert R ^a   Hoffmann, Vicki Poole ^a   Witte, Michael M ^a   Zhao, Fangyi ^a   Houston, John P ^a,b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ILOPERIDONE; RISPERIDONE;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA DETERMINATION; DRUG RESPONSE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GFRA2 GENE; GRIA4 GENE; HUMAN; MAJOR CLINICAL STUDY; NPAS3 GENE; NUDT9P1 GENE; OUTCOME ASSESSMENT; PHARMACOGENOMICS; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SEROTONIN RECEPTOR 7 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TNR GENE; XKR4 GENE;

EID: 84859127469     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06507     Document Type: Article

References (20)

1. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response toatypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102(1-3):230-240. doi:10.1016/j.schres.208.02.021 PubMed
2. Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response toantipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35(2):581-590. doi:10.1038/np.209. 164 PubMed
3. Ascher-Svanum H, Nyhuis AW, Faries DE, et al. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34(6):1163-1171. doi:10.1093/schbul/sbm134 PubMed
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792. doi:10.1056/NEJM201031534101 PubMed (Pubitemid 32222155)
5. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-726. doi:10.120/JCO.20.3. 719 PubMed (Pubitemid 34111379)
6. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007; 12(8):707-747. doi:10.1038/sj.mp.40209 PubMed (Pubitemid 47172693)
7. Steimer W. Pharmacogenetics and psychoactive drug therapy: ready for the patient? Ther Drug Monit. 2010;32(4):381-386. doi:10.1097/FTD.0b013e3181e1a78d PubMed
8. Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry. 2009;14(8):804-819. doi:10.1038/mp.208.56 PubMed
9. Volpi S, Potkin SG, Malhotra AK, et al. Applicability of agenetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry. 2009;70(6):801-809. doi:10.408/JCP.08m04391 PubMed
10. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed (Pubitemid 18039085)
11. Fijal BA, Kinon BJ, Kapur S, et al. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J. 2009;9(5):311-318. doi:10.1038/tpj.209.24 PubMed
12. Jurinke C, van den Boom D, Cantor CR, et al. Automated genotyping using the DNA MassArray technology. Methods Mol Biol. 2002;187:179-192. PubMed
13. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74(4):765-769. doi:10.1086/383251 PubMed (Pubitemid 38420107)
14. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-238. doi:10.1016/j.schres.205.04.08 PubMed (Pubitemid 41457263)
15. Ioannidis J, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci U S A. 2001;98(3):831-836. doi:10.1073/pnas.0215298 PubMed (Pubitemid 32121147)
16. Ioannidis JP, Trikalinos TA, Ntzani EE, et al. Genetic associations in large versus small studies: an empirical assessment. Lancet. 2003;361(9357): 567-571. doi:10.1016/S0140-6736(03)12516-0 PubMed (Pubitemid 36207475)
17. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124. doi:10.1371/journal.pmed.020124 PubMed
18. Ioannidis JP, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet. 2001;29(3):306-309. doi:10.1038/ng749 PubMed (Pubitemid 33096456)
19. May PR, Van Putten T, Yale C. Predicting outcome of antipsychotic drug treatment from early response. Am J Psychiatry. 1980;137(9):1088-1089. PubMed (Pubitemid 10048887)
20. Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry. 2007;68(3):352-360 (Pubitemid 46506798)